gut microbiota metabolic syndrome
Conditions
Interventions
Male or female postmenopausal metabolic syndrome patients will be randomised to
receive either (N=12) autologous faecal transplantation followed by 4 grams of
oral butyrate tablets once daily for 4
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Caucasian male or postmenopausal female - 50-70 years old - BMI *30 kg/m2 - At least 3 out of 5 NCEP metabolic syndrome criteria: fasting plasma glucose * 5.6 mmol/l, triglycerides * 1.7 mmol/l, waist-circumference > 102 cm (m) / > 88 cm (f), HDL-cholesterol * 1.04 mmol/l (m) / * 1.30 mmol/l (f), blood pressure * 130/85 mmHg
Exclusion criteria
Exclusion criteria: - Medication use, including PPI and antibiotics in last 3 months - Smoking, XTC, amphetamine or cocaine abuse - Alcohol abuse (>3/day) - Participation in a research protocol involving radiation exposure in the last 2 years. - eGFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in insulin sensitivity and lipolysis (including lipid content in muscle biopsies), as measured by a hyperinsulinemic euglycemic clamp and satiety as measured by validated eating behaviour questionnaires in combination with cerebral binding of the radioligand [123I]FP-CIT to serotonin transporters (as visualised by SPECT-scan) related to small intestinal serotonin levels in small intestinal biopsies. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in faecal and small intestinal microbiota composition in relation to faecal energy excretion (24h faeces), resting and physical activity (accelerometers) intestinal permeability (faecal calprotectin levels), intestinal passage time (Sitzmark capsules), sympathetic tone (Nexfin) and plasma markers of low grade inflammation (LPS), glucose and lipid metabolism (proteomics), liver fat (MRI). | — |
Countries
Netherlands
Outcome results
None listed